Restore Mind Medicine
Table of Contents
Questions to the Company for MM-110
Unkept Promises in Other Clinical Trials
The Tales of Digital Medicine
I.
||.
Executive Summary
Introduction
Severe Market Underperformance
Comparative Performance
Our History of Engagement
The Irrefutable Need For Change
Board Fails to Hold Management Accountable
Change is Fundamentally Required for Survival
Non-Supported Directors
Our Plan to Restore Value
100 Day Plan
Our Nominees' Commitment to MindMed
We Are Aligned with Shareholders
Our Exception Nominees v. Incumbents
A Flawed Approach to Clinical
Development
Flawed Clinical Development Strategy
Delayed Clinical Development Pipeline
Clinical Development Nomenclature
MM-120 Background
The Unprecedented Phase llb
Results of FCM's FDA Study
CEO Robert Barrow
CMO Danial Karlin
Setting the Record Straight
Flawed Approach for Phase llb
The Unnecessary Phase Ilb is Also Delayed
MindMed "On-Track"
Categorical Failure of MM-110 Program
Categorical Failure of MM-110 Program Pt2
The Disparity Between MindMed and the FDA
6
7
8
9
11
16
17
18
19
20
21
22
23
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
III.
IV.
V.
VI.
Destructive and Dilutive
Financing Approach
Destructive, Dilutive Financing
MindMed's Purported Reasons
Excessive G&A Expenses
Poor Use of Capital and Expense Controls
G&A and Headcount Out of Line
Poor Capital Allocation
Overemphasis on Commercialization
Redundant Staffers & C-Suite
Executive Compensation &
Corporate Governance
Minimally Aligned Board
Director Over-Compensation
Outsized Executive Compensation
Poorly Designed Executive Compensation
Structure
"Rubberstamped" Executive Compensation
Poor Corporate Governance Practices
Our Plan to Restore Value
MM-120 for GAD
Bringing MM-120 to Market Quickly and Safely
Trial Diagram
FDA Accelerated Approval
40
41
42
45
46
48
49
50
51
52
54
55
56
57
58
59
62
63
64
Key Dates MM-120 Strategy
Other Clinical Development
Programs & Digital Medicine
MM-110 Preclinical Safety Studies
MM-402
Digital Medicine
Other Clinical & Pre-clinical Programs
R&D Personnel
MindMed R&D Personnel Breakdown
Proposed Organization Chart
R&D Budget
External R&D Collaborations
R&D Proposed Budget
G&A
Commitment for Judicious Use of
Shareholder Capital
Align G&A and Headcount.
Executive Personnel
G&A Personnel
G&A Budget for Q4 2023 - Q3 2024
Combined Budget
Transition Cost
Cash Projection
Governance & Investor Relations
Pay for Performance
65
67
68
69
70
72
73
74
75
78
79
80
81
82
83
84
85
87
VII.
Say-on-Pay
Investor Relations Enhancements.
Our Nominees
Dr. Scott Freeman
Dr. Farzin Farzaneh
Mr. Vivek Jain, CPA
Mr. Alexander Wodka, CPA
References
88
89
91
92
93
94
95
3View entire presentation